EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience

Raghava Kashyap iD, Ramin Alipour, Emma Boehm, Kerry Jewell, Aravind S RaviKumar, Anthony Cardin, Javad Saghebi, Michael S Hofman, Michael T Fahey, Michael Michael, Tim Akhurst, Rodney J Hicks und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07235-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Raghava Kashyap und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. kashyapkr@gmail.com. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Octreotide, Organometallic Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Melbourne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Patients with gastro-entero-pancreatic neuroendocrine tumours (GEP NET) who retain somatostatin receptor (SSTR) expression after initial response to [ 177 Lu]Lu-DOTA-Octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) are amenable to re-treatment (R-PRRT) upon progression. We assessed the safety and efficacy of R-PRRT in patients with progressive metastatic GEP NET. Materials and methods A retrospective analysis, approved by institutional ethics board, was performed in patients with GEP NET who received R-PRRT for either symptomatically or radiologically progressive disease. Safety was assessed by renal and haematological parameters at 3 months post R-PRRT (CTCAE v5.0). Molecular imaging response was evaluated on [ 68 Ga]Ga-DOTA-Octreotate (GaTate) PET/CT using pre-defined criteria. RECIST 1.1 responses 3 months post R-PRRT were documented when feasible. Progression-free and overall survival analysis were performed.

Results

A total of 63 patients had R1-PRRT (1–3 cycles). The majority (70%) had Grade 2 NET and small intestinal primary (51%). A second re-treatment course (R2-PRRT) was given in 20 patients and a third course (R3-PRRT) in 6 patients. Glomerular filtration rate (GFR) was stable following R1-PRRT. Following R2-PRRT, worsening GFR from CTCAE G2 to G3 was seen in 10% (2/20) of patients, but none after R3-PRRT. Grade 3 thrombocytopenia occurred in 2 patients after R1-PRRT and in 1 patient after R3-PRRT. Grade 4 thrombocytopenia was observed in 1 patient post R1-PRRT. Following R1-PRRT, RECIST 1.1 responses CR, PR, SD was 0%, 10%, 76%, respectively. Disease control rate on GaTate PET/CT was 52/58 (89%) post R1-PRRT. Median progression free survival (PFS) following R1-PRRT was 1.6 years (95% CI:1.2–2.3).

Conclusion

R-PRRT is feasible, tolerable and efficacious in achieving disease control in patients with progressive GEP NET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsOctreotideOrganometallic CompoundsIntestinal NeoplasmsSafetyStomach NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeAdultDisease ProgressionRadiopharmaceuticalsCoordination Complexes

Stichwörter der Autor:innen

DOTATATERe-TreatmentGastroenteropancreatic (GEP)Neuroendocrine neoplasms (NENs)PRRTLutetium-177

Substanzen

OctreotideOrganometallic Compounds177Lu-DOTA-octreotateRadiopharmaceuticalsCoordination Complexes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. kashyapkr@gmail.com.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. kashyapkr@gmail.com.
  • Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, 3000, Australia. kashyapkr@gmail.com.
  • Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Department of Clinical Pathology, Collaborative Centre for Genomic Cancer Medicine, University of Melbourne, Melbourne, VIC, Australia.

ORCID-Profile: Raghava Kashyap

Förderung

  • University of Melbourne

Zitieren

APA

Kashyap, R., Alipour, R., Boehm, E., Jewell, K., RaviKumar, A. S., Cardin, A., Saghebi, J., Hofman, M. S., Fahey, M. T., Michael, M., Akhurst, T., Hicks, R. J., & Kong, G. (2025). Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07235-w

Vancouver

Kashyap R, Alipour R, Boehm E, Jewell K, RaviKumar AS, Cardin A, et al. Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07235-w

BibTeX
@article{Kashyap2025,
  author = {Kashyap, Raghava and Alipour, Ramin and Boehm, Emma and Jewell, Kerry and RaviKumar, Aravind S and Cardin, Anthony and Saghebi, Javad and Hofman, Michael S and Fahey, Michael T and Michael, Michael and Akhurst, Tim and Hicks, Rodney J and Kong, Grace},
  title = {Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07235-w}
}
Kostenlos starten →